UC Davis joins as trial site in pivotal Phase III trial

Charles De Mesa, DO, MPH, a Northern California practicing specialist in anesthesiology and pain medicine, physical medicine and rehabilitation and musculoskeletal pain medicine is GID Bio’s newest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis.  

Dr. De Mesa leads a team of eight physicians who specialize in sports and family medicine, and have collectively treated athletes ranging from “weekend warriors” to professionals.

The team at UC Davis joins Tulane University School of Medicine, Texas Center for Cell Therapy and Research in San Antonio, OrthoCarolina, Wake Forest School of Medicine and New Jersey Regenerative Institute led by Jaime Garza, MD, DDS, FACS, Claude Moorman, and Gerald Malanga, MD,  respectively. 

For more information about the trial, visit clinicaltrials.gov.

Our cell therapy is not approved by the FDA for sale or use in the U.S.